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76 Poster Session-Iand 606 7.8%, respectively. The 1 and 5yr overall survival (OS) for
pts with non-malignant disease was 826 6.6%. The 5yr OS in chil-
dren with PGF was 45.5 6 15%. In conclusion, RI-AlloSCT is safe
and well tolerated in children; RI-AlloSCT is associated with signif-
icantly lower NRM and high sustained donor chimerism. However,
chemo-naı¨ve children receiving UCB have a higher incidence of
PGF and need alternative conditioning.205
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION IS AN
EFFECTIVE THERAPY FOR WISKOTT-ALDRICH SYNDROME
Sun, J.M., Driscoll, T., Prasad, V.K., Parikh, S., Szabolcs, P.,
Kurtzberg, J., Martin, P.L. Duke University, Durham, NC
Background: Patients with severe Wiskott-Aldrich Syndrome
(WAS) characterized by absent WAS protein rarely survive beyond
20 years. Infections, hemorrhage and malignancy are leading causes
of death. Allogeneic bone marrow transplant corrects immune func-
tion and thrombocytopenia and prolongs survival. However, many
children lack an appropriate donor. This study investigated the fea-
sibility of unrelated umbilical cord blood (UCB) as an alternative
source of stem cells in WAS patients lacking HLA-matched bone
marrow donors.
Methods: Fifteen children with severe WAS received 16 unre-
lated UCB transplants at Duke University from 2/1998 to 12/
2007. All patients received myeloablative chemotherapy (busulfan,
cyclophosphamide, ATG 6 fludarabine). Patients were evaluated
for engraftment, graft versus host disease (GvHD), survival and ef-
fects on the natural history of disease.
Results:UCB units matched at$4/6 HLAmarkers had a median
precryopreservation total nucleated cell dose of 7.95  107 cells/kg.
All patients engrafted with donor cells (one after a second UCB
transplant). Median times to neutrophil (ANC. 500/uL) and plate-
let (.50k/L) engraftment were 21 (range 10–38) and 67 (range 46–
139) days, respectively. One patient has mixed chimerism, all others
maintained complete donor chimerism post-transplant. Four
patients experienced grade II-IV acute GvHD and 11/12 evaluable
patients experienced limited (n 5 10) or extensive (n 5 1) chronic
GvHD. Six patients died post-transplant of gut GvHD with adeno-
virus, extensive chronicGvHDwith EBV lymphoproliferative disor-
der, multisystem organ failure, and three of infection alone
(Klebsiella, parainfluenza, adenovirus). Nine patients are surviving
with a median follow-up of 89 months (range 9–127), an overall sur-
vival of 60%. Survivors have normal platelets, minimal eczema or
other medical issues. All school-age children are attending school.
Conclusions:Unrelated UCB is a readily available source of stem
cells for patients with WAS. UCB transplant corrects the immuno-
deficiency and thrombocytopenia caused byWAS and favorably im-
pacts the natural history of disease. An increased incidence of limited
chronic skin GvHD was noted compared to that reported in UCB
transplant recipients with other diagnoses, perhaps related to pro-
inflammatory state of the skin due to pre-transplantWAS-associated
eczema. UCB transplantation should be considered for all patients
with severe WAS lacking a matched adult or related bone marrow
donor.206
SIGNIFICANCE OF HLA-B ANTIGEN MATCHING IN EVENT FREE SURVIVAL
(EFS) IN PEDIATRIC UMBILICAL CORD BLOOD TRANSPLANTATION
(CBT): EXPERIENCE FROM 124 SINGLE CBT AT CHILDREN’S MEMORIAL
HOSPITAL (CMH), CHICAGO
Merchant, M., Chaudhury, S., Duerst, R., Jacobsohn, D., Tse, W.T.,
Schneiderman, J., Kletzel, M. Children’s Memorial Hospital, Northwest-
ern University Feinberg School of Medicine, Chicago, IL
Objective: To evaluate the significance of HLA antigen match-
ing/ mismatching in CBT outcomes in the pediatric patient.
Method: Between 1995- 2007, 124 single CBTwere performed at
CMH for treatment of malignancy (85) or non-malignancy (39). Dis-
eases included ALL (39), AML (29), MDS (7), NBL (2), other malig-
nancies (8), SCID (11), THAL (3), WISK (3), Osteopetrosis (4), AA
(2), Fanconi’s (2), other non-malignancies (14). Status at transplant
for malignancies: CR1 (42%), CR2 (44%), CR $3 (7%) and PR(7%). Cord blood units were processed as described by Rubenstein
et al. Recipients were 55 female, 69 male, median age at transplant
3.7 yrs (0.56 – 20.8), weight 20 kg (3- 73). 113 pts (91%) received
myelo-ablative therapy of fTBI 6 VP, Cy, TT (84), Bu, Cy 6 VP
(21) or TT, Cy 6 FLUD (8) 11 pts (9%) received non-ablative reg-
imen of VP, Cy, or FLUD 6 Bu, Cy. GVHD prophylaxis was CSA
1MTX 1 ATG . Prior to 2000, HLA matching for class was done
by serologic typing. Later, high level molecular typing was done for
HLA-DRB1. Degree of HLA matching was 6/6 (13), 5/6 (29), 4/6
(74), 3/6 (7). 5/6 HLA group: single mismatch on HLA-A (13),
HLA-B (10), HLA-DRB1 (6). 4/6 HLA group: 2 mismatches,
HLA-B (9) and DRB1 (1); other 64 pts had 1 mismatch on different
antigens: A (43), B (51), DRB1 (34). 3/6HLA group: 4 pts had 1 mis-
match on each HLA antigen 3 patients had 2 mismatches on HLA-B
1 another mismatch. 30 patients (24%) died of TRM. 17 of 85 pts
(20%) relapsed. 39% developed acute GVHD grade II/IV and
6.5% chronic GVHD. OS is 56% and EFS is 48% with median fol-
low up of 763 days.
Results: Matching/mismatching at HLA-A, or HLA-DRB1
showed no statistical significance in TRM or EFS. Degree of
HLA-B matching showed statistical significance in TRM and EFS
(p-value 0.001). EFS, HLA-A: 1 match 56.5%; 2 matches 54.9%.
EFS, HLA-B: 0 match 18.3%; 1 match 48.6%; 2 matches 72.3%.
EFS, HLA-DRB1: 1 match 64%; 2 matches 51.1%. TRM, HLA-
B: 11% (2 matches, n 5 46), 31% (1 match, n5 65); 42% (0 match,
n5 12). However, in analyzing the 4/6 HLA group alone, TRM for
HLA-B antigen was 7% (2 matches), 25% (1 match) and 22% (0
match). In this group, the rate of relapse for pts with malignancy
was 18% (2 matches), 5.7% (1 match) and 83.3% (0 match).
Conclusion: In pediatric CBT, TRM and Relapse increase with
increasing HLA-B mismatch; and Event Free Survivals improve
when HLA-B antigens are matched.207
TARGETING TO AN OPTIMAL AUC OF INTRAVENOUS BUSULFAN PRE-
VENTS GRAFT FAILURE IN TRANSPLANTATION IN CHILDREN WITH
NON-MALIGNANT DISEASES
Bartelink, I.H.1, Bredius, R.G.M.2, Bierings, M.1, Egeler, M.2,
Lankester, A.C.2, Egberts, T.C.G.1, Zwaveling, J.2, Boelens, J.J.1
1UMCU, Utrecht, Netherlands; 2LUMC, Leiden, Netherlands
Background: Busulfan combined with therapeutic drug monitor-
ing guided dosing is associated with higher event free survival (EFS)
rates due to less graft-failure/relapses and lower toxicity in haemato-
logical stem cell transplantation (HSCT). In an earlier study, our
group showed an optimal AUC between 74–82 mg*h/L with respect
to event free survival (EFS) in a group of children withmalignant and
non-malignant indications. Non-malignant diseases, especially in-
born error of metabolism (IEM) are known to be associated with
high graft-failure rates. Therefore we analysed the influence of the
‘‘lower’’ limit of the (previously found) optimum of Busulfan AUC
on graft-failure.
Methods: All children, transplanted between 2001–2008 in 2
Dutch pediatric transplant centers, receiving intravenous busulfan
as part of a myeloablative regimen for non-malignant indications,
were included. The association between an AUC below or above
the lower limit of the optimum (74mg*h/L) and the main endpoints
graft-failure and EFS and the toxicity endpoints treatment related
mortality (TRM), acute-Graft-versus-Host Disease grade 2–4
(aGvHD) and Veno-occlusive Disease (VOD), were tested using
uni- and multivariable Cox regression analysis.
Results: 70 patients were included (28 patients with IEM, 36 with
immune defiencies (including Hemophagocytic Lympho-Histiocy-
tosis) and 5 patients with bone marrow failures). Indications were
equally distributed over the 2 groups. The median follow up time
was 2.5 years (range 1–370 weeks). The AUC in the lower group
ranged from 35.0–73.7 mg*h/L while those in the higher group
ranged from 74.5 to 98.7 mg*h/L. EFS-rate in the \74mg*h/L
group was negatively influenced by Graft-failure (18%, vs 0% in pa-
tients receiving.74mg*h/L,HR5 0.2, P5 0.016). EFSwas 72% vs
82% in the \74 mg*h/L and .74 mg*h/L group, respectively.
aGvHD grade 2–4 did occur more frequently in patients receiving
a high exposure of busulfan (5% vs 19%: p 5 0.2). No difference
in TRM (P5 0.8) and VOD (P5 0.9) occurrence was noted as well.
